A not-so small addition to my earlier reply to your question, Michael.
It is now more apparent than ever that PPHM would greatly benefit from just one FDA approval for an indication in oncology or the like. Whether that actual approval is necessary to gain some advantage/benefit from the SDNY decision and opinion in Amarin et al v. FDA is another subject I will leave to others to discuss, pro and con. The crux is that information imparted by a company about a product to others must be truthful, and not misleading.
The following appeared on the Amarin web-site earlier today, as you may know by now. It amounts to a corporate presentation that could be used at conferences or other locations:
It has not taken long for the share price and volume of AMRN to accelerate in the short time[~1 1/2 hrs] since I first saw the above link.
PPHM has a great deal of information that it has accumulated re Bavi resulting from efforts of others. It would include the info that CJG has carefully accumulated in the "stickies" above. What, if anything, can be further done with that truthful and not misleading information?
News 
Market Data 
Discover 
